| 前收市價 | 56.95 |
| 開市 | 56.95 |
| 買盤 | 57.35 |
| 賣出價 | 58.20 |
| 拍板 | 75.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 56.95 - 56.95 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 342 |
BenzingaMerck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
On Tuesday, Merck & Co Inc (NYSE:MRK) shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease. Clesrovimab met its primary safety and efficacy endpoints in the trial, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150. Participants were randomized to
ZacksShould You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
Motley FoolBillionaires Are Loading Up on This Surging Dow Stock. Should You?
Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin.
